BiotechTube
QT Imaging

QT Imaging

Novato, United States· Est.
qtimaging.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $40M

Overview

QT Imaging is commercializing a novel breast imaging platform designed to address key limitations of current standards like mammography, particularly for women with dense breast tissue. Its technology, Quantitative Transmission (QT) ultrasound, generates 3D speed-of-sound maps to differentiate tissue types, enhanced by AI for lesion classification. The company is in the commercial stage, having received regulatory clearances including in the UAE, and is positioning its system as a safer, more accessible, and potentially more accurate alternative for screening and diagnostic workflows.

Oncology

Technology Platform

Quantitative Transmission (QT) ultrasound platform combining 3D whole-breast acoustic computed tomography (CT), AI-powered lesion classification, and quantitative tissue biomarkers (speed-of-sound maps) for breast imaging.

Funding History

2
Total raised:$40M
Series B$25M
Series A$15M

Opportunities

Large addressable market driven by the limitations of mammography for the 40-50% of women with dense breasts.
The non-ionizing, compression-free technology enables deployment in low-resource and mobile settings, expanding access to care.
Integration of AI and biomarkers offers a pathway to improved diagnostic accuracy and reduced overdiagnosis.

Risk Factors

Facing entrenched competition from mammography, ultrasound, and MRI, requiring significant effort to change clinical practice.
Commercial success depends on securing widespread insurance reimbursement and building an effective sales distribution network.
As a public company, it must manage investor expectations while likely still operating at a net loss during commercial scale-up.

Competitive Landscape

Competes directly with established breast imaging modalities: X-ray-based Digital Mammography/Tomosynthesis (DBT), handheld and Automated Breast Ultrasound (ABUS), and Breast MRI. Key differentiators are the absence of ionizing radiation/compression and the provision of quantitative biomarkers. Must also compete with other novel modalities and AI software add-ons for existing imaging systems.

More companies in Diagnostics & Precision Medicine →More companies in United States →